[{"orgOrder":0,"company":"Biosergen","sponsor":"Alkem Laboratories | JSS Medical Research Asia Pacific","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BSG005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biosergen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosergen \/ Alkem Laboratories | JSS Medical Research Asia Pacific","highestDevelopmentStatusID":"7","companyTruncated":"Biosergen \/ Alkem Laboratories | JSS Medical Research Asia Pacific"},{"orgOrder":0,"company":"Biosergen","sponsor":"Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BSG005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biosergen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosergen \/ Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network","highestDevelopmentStatusID":"7","companyTruncated":"Biosergen \/ Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network"},{"orgOrder":0,"company":"Biosergen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BSG005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biosergen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosergen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biosergen \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Biosergen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BSG005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Invasive Fungal Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 07, 2024

                          Lead Product(s) : BSG005

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Alkem Laboratories | JSS Medical Research Asia Pacific

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of laboratory and preclinical studies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 08, 2022

                          Lead Product(s) : BSG005

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Lead Product(s) : BSG005

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : BSG005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Invasive Fungal Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 10, 2021

                          Lead Product(s) : BSG005

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Select Pharma Laboratories LTD | GreenLight Clinical | Nucleus Network

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank